Parathyroid hormone replacement in hypoparathyroidism
Sharon Hsiao-Han Chou, Tamara Vokes · Clinical Investigation · 2015
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Clinical Investigation · OMICS Publishing Group · article · 2015
Abstract
Hypoparathyroidism results from insufficient parathyroid hormone (PTH) to maintain normal serum levels of calcium and phosphate. Unlike most endocrine deficiency disorders, the current standard of treatment is not replacement with PTH but supplementation with calcium and vitamin D. Normal physiology cannot be fully restored with calcium and vitamin D, and long-term complications of this treatment include impaired renal function, nephrolithiasis and ectopic soft tissue calcification. In the last decade clinical studies have emerged using PTH for the treatment of hypoparathyroidism either in place of or in addition to standard treatment with calcium and vitamin D.
The effects of PTH replacement on biochemical indices, bone metabolism and quality of life have been promising.
Open the resolved locator · 10.4155/cli.14.136
Metadata licence: OpenAlex metadata (CC0)